TNFα-neutralizing antibodies
US8444984B2 · kind B2 · utility
1Cited by
1References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 7, 2012 |
| Grant date | May 21, 2013 |
| Priority date | — |
| Expiry date | Jun 7, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/20
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides monoclonal antibodies that neutralize TNFα activity. The monoclonal antibodies may be rabbit monoclonal antibodies or monoclonal antibodies having CDR regions derived from those rabbit monoclonal antibodies. In certain embodiments, the monoclonal antibodies may be humanized. Methods of using the subject antibodies to inhibit TNFα activity, methods of treatment using those antibodies and kits containing the same are also provided. The invention finds use in a variety of research and medical applications.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.